Journal
VACCINES
Volume 11, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/vaccines11091440
Keywords
immunogenic cell death; nanotechnology; tumor vaccines; cancer immunotherapy
Categories
Ask authors/readers for more resources
This review summarizes the latest studies on nanotechnology-mediated immunogenic cell death for effective cancer immunotherapy and highlights the challenges.
Tumor vaccines have been used to treat cancer. How to efficiently induce tumor-associated antigens (TAAs) secretion with host immune system activation is a key issue in achieving high antitumor immunity. Immunogenic cell death (ICD) is a process in which tumor cells upon an external stimulus change from non-immunogenic to immunogenic, leading to enhanced antitumor immune responses. The immune properties of ICD are damage-associated molecular patterns and TAA secretion, which can further promote dendritic cell maturation and antigen presentation to T cells for adaptive immune response provocation. In this review, we mainly summarize the latest studies focusing on nanotechnology-mediated ICD for effective cancer immunotherapy as well as point out the challenges.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available